Cargando…
Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly applic...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474991/ https://www.ncbi.nlm.nih.gov/pubmed/34631459 http://dx.doi.org/10.5498/wjp.v11.i9.543 |